Onkológia 3/2014

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

Multiple myeloma (MM) is the second most common hematological malignancy and despite recent advances in the MM-treatment, the disease still remains incurable; necessitating a search for new therapeutic agents. Pomalidomide is a potent second-generation immunomodulatory agent with direct antiproliferative, pro-apoptotic, and antiangiogenic effects, as well as modulatory effects on bone resorption and on the immune system. In this report we provide a summary of results from a phase III trial that compared the efficacy and safety of pomalidomide plus low-dose dexamethasone with high-dose dexamethasone in patients with refractory or relapsed and refractory MM.

Keywords: multiple myeloma, pomalidomide.